Application of lupenone to preparation of drug for prevention and/or treatment of senile dementia and preparation

A technology of lupenone and senile dementia, applied in preparations, the application field of lupenone in the preparation of drugs for the prevention and/or treatment of senile dementia, which can solve the problems of many side effects

Active Publication Date: 2016-07-27
JIANGSU KANION PHARMA CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the etiology of AD is unknown, there is no drug that can effectively reverse the progression of the disease in the current treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lupenone to preparation of drug for prevention and/or treatment of senile dementia and preparation
  • Application of lupenone to preparation of drug for prevention and/or treatment of senile dementia and preparation
  • Application of lupenone to preparation of drug for prevention and/or treatment of senile dementia and preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] 1. Lupenone on Aβ 25-35 Improvement of protein-induced symptoms in senile dementia mice

[0027] 1.1 Experimental animals and reagents

[0028] Experimental animals: 50 clean-grade healthy male Kunming mice, weighing 26-30 g, were purchased from the Comparative Medicine Center of Yangzhou University. Reagent: lupenone (purity is 91%), provided by Jiangsu Kangyuan Pharmaceutical Co., Ltd.; Aβ 25-35 Purchased from sigma company; ChAT and AchE detection kits were purchased from Nanjing Jiancheng Bioengineering Institute; Naofukang was purchased from Hubei Huazhong Pharmaceutical Co., Ltd.

[0029] 1.2 Condensed Aβ 25-35 preparation of

[0030] 1mgAβ 25-35 Dissolve in 943μl sterilized physiological saline at a concentration of 1mmol / L, seal it and place it in a 37℃ cell culture incubator for 5-7d incubation to make it into condensed Aβ 25-35 , placed in a -20°C freezer for later use.

[0031] 1.3 Preparation and administration of mouse AD model

[0032] After the mi...

Embodiment 2

[0053] 2. Effect of lupenone on D-galactose and AlCl 3 Protective effect of induced compound senile dementia in rats

[0054] 2.1 Experimental animals and reagents

[0055] Experimental animals: aged healthy male Wistar rats, weighing 350-390 g, a total of 75 were purchased from the Comparative Medicine Center of Yangzhou University. Reagent: lupenone (purity is 91%), provided by Jiangsu Kangyuan Pharmaceutical Co., Ltd.; D-galactose, AlCl 3 Bought from Sinopharm Chemical Reagent Co., Ltd.; SOD, MDA, and CAT activity detection kits were purchased from Nanjing Jiancheng Bioengineering Research Institute; Naofukang was purchased from Hubei Huazhong Pharmaceutical Co., Ltd.

[0056] 2.2 Preparation and administration of compound senile dementia animal model

[0057] Experimental Wistar rats were randomly divided into control group, model group, Naofukang group, lupenone I group, and lupenone II group, with 15 rats in each group. The model group and the treatment group were gi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of lupenone to preparation of a drug for prevention and/or treatment of senile dementia. Animal experiments indicate that lupenone has a high protection effect on a mouse with senile dementia caused by A beta 25-35 and a rat with senile dementia caused by D-galactose and AlCl3, the learning and memorizing functions can be remarkably improved, the activity of acetylcholin esterase (AchE) in brain tissue and the content of malonaldehyde (MDA) in blood can be obviously reduced, the content of choline acetyl transferase (ChAT) in the brain tissue and superoxide dismutase (SOD) and catalase (CAT) in the blood can be obviously increased, the abnormal phosphorylation level of Tau protein is lowered, and therefore lupenone can be used for preparing the drug for prevention and treatment of senile dementia.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to the application of lupenone in the preparation of medicines for preventing and / or treating senile dementia and a preparation. Background technique [0002] Alzheimer's disease (AD) is a degenerative disease of the central nervous system with progressive cognitive impairment and memory impairment as the main clinical manifestations. Current studies believe that dementia is related to the degeneration of cerebral cortex and subcortical nerve cells, and the exact etiology is still inconclusive. Pathophysiological studies have found that a large number of neurons in the neocortex, hippocampus, basal ganglia, and locus coeruleus of the brain of patients with Alzheimer's disease are lost, accompanied by serotonin, norepinephrine, and somatostatin releasing factor. The concentration of a neurotransmitter in the brain decreases, especially the decrease of acetylcholine, which leads to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61P25/28
CPCA61K31/56
Inventor 萧伟陶晓倩张新庄李娜曹亮王振中丁岗
Owner JIANGSU KANION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap